Repository logo
 
Publication

HBV-Associated Acute Liver Failure After Immunosuppression and Risk of Death.

dc.contributor.authorKarvellas, C
dc.contributor.authorCardoso, F
dc.contributor.authorGottfried, M
dc.contributor.authorReddy, R
dc.contributor.authorHanje, A
dc.contributor.authorGanger, D
dc.contributor.authorLee, W
dc.date.accessioned2016-11-28T15:32:34Z
dc.date.available2016-11-28T15:32:34Z
dc.date.issued2016
dc.description.abstractBACKGROUND & AIMS: Acute liver failure (ALF) caused by hepatitis B virus (HBV) infection can occur after immunosuppressive treatment and be fatal, although it might be preventable. We aimed to characterize the causes, clinical course, and short-term outcomes of HBV-associated ALF after immune-suppressive therapy, compared with patients with HBV-associated ALF without immunosuppression (control subjects). METHODS: We performed a retrospective multicenter study of 156 consecutive patients diagnosed with HBV-associated ALF (22 with a solid or blood malignancy) enrolled in the Acute Liver Failure Study Group registry from January 1998 through April 2015. We collected data on results of serologic and hepatic biochemistry analyses, grade of hepatic encephalopathy, Model for End-Stage Liver Disease score, and King's College criteria. We also collected data on clinical features, medical therapies, and complications in the first 7 days following study enrollment. Logistic regression was used to identify factors associated with transplant-free survival at 21 days in HBV-associated ALF (the primary outcome). RESULTS: Among patients with HBV-associated ALF, 28 cases (18%) occurred after immunosuppressive therapy (15 patients received systemic corticosteroids and 21 received chemotherapy); and 128 cases did not (control subjects, 82%). Significantly greater proportions of patients with HBV-associated ALF after immunosuppression were nonwhite persons, and had anemia or thrombocytopenia than controls (P < .02 for all). The serologic profile of HBV infection, severity of liver failure (based on MELD score), and complications (hepatic encephalopathy or need for mechanical ventilation, vasopressors, or renal replacement therapy) were similar between the groups (P>.17 for all). Factors associated with 21 day transplant-free survival were increased MELD score (odds ratio ∼OR, 0.894 (95% confidence interval 0.842-0.949 per increment), requirement for mechanical ventilation (OR 0.111(0.041-0.300), and immunosuppressive therapy (OR 0.274(0.082-0.923)). CONCLUSIONS: Within a cohort study of patients with HBV-associated ALF, 18% had received immunosuppressive therapy. Significantly smaller proportions of patients with HBV-associated ALF after immunosuppression survive beyond 21 days than patients with HBV-associated ALF who did not receive immunosuppression. Patients undergoing chemotherapy should be screened for HBV infection and given appropriate antiviral therapies to reduce preventable mortality.pt_PT
dc.identifier.citationClin Gastroenterol Hepatol. 2016 Jun 13. pii: S1542-3565(16)30305-6pt_PT
dc.identifier.doi10.1016/j.cgh.2016.06.008pt_PT
dc.identifier.issn1542-7714
dc.identifier.urihttp://hdl.handle.net/10400.10/1770
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherAmerican Gastroenterological Associationpt_PT
dc.subjectAcute liver failurept_PT
dc.subjectHepatitis Bpt_PT
dc.subjectFalência hepática agudapt_PT
dc.titleHBV-Associated Acute Liver Failure After Immunosuppression and Risk of Death.pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlacePhiladelphiapt_PT
oaire.citation.titleClinical gastroenterology and hepatologypt_PT
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Clin Gastroenterol Hepatol. 2016 Jun 13.pdf
Size:
259.45 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: